Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Srovnání standardní péče s trojkombinací cílených imunoterapeutických látek

21. října 2026 aktualizováno: National Cancer Institute (NCI)

Randomizovaná studie fáze II s tripletovou terapií (PD-L1 inhibitor durvalumab (MEDI4736) v kombinaci s olaparibem a cediranibem) ve srovnání s olaparibem a cediranibem nebo durvalumabem (MEDI4736) a cediranibem nebo standardní chemoterapií rekurentní péče u žen s epitheliem platistou Rakovina vaječníků, primární peritoneální rakovina nebo rakovina vejcovodů, kteří dříve dostávali bevacizumab

This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement with platinum therapy (recurrent platinum resistant). Usual treatment is the type of treatment most patients with this condition receive if they are not part of a clinical study. Combination therapies studied in this trial include MEDI4736 (durvalumab) plus olaparib and cediranib, durvalumab and cediranib, or olaparib and cediranib. Monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumors cells to grow and spread. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Cediranib may stop the growth of tumor cells by blocking VEGF (an enzyme). needed for cell growth. Giving different combinations of durvalumab, olaparib and cediranib may work better in increasing the duration of time that the cancer does not progress compared to the usual treatment.

Přehled studie

Postavení

Aktivní, ne nábor

Podmínky

Intervence / Léčba

Detailní popis

PRIMARY OBJECTIVE:

I. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by progression-free survival (PFS), as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who had prior bevacizumab.

SECONDARY OBJECTIVES:

I. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who had prior bevacizumab.

II. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by overall survival (OS), as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who had prior bevacizumab.

OUTLINE: Patients are randomized to 1 of 4 arms.

ARM I: Patients receive paclitaxel intravenously (IV) over 60 minutes on days 1, 8, and 15, or pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8 and 15 or days 1-5 per the discretion of the treating physician. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and as clinically indicated on study. Patients also undergo collection of blood and computed tomography (CT) with contrast during screening, and CT or magnetic resonance imaging (MRI) scans throughout the trial.

ARM II: Patients receive durvalumab IV over 60 minutes on day 1, cediranib maleate orally (PO) once daily (QD) Monday through Friday, and olaparib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.

ARM III: Patients receive durvalumab IV over 60 minutes on day 1 and cediranib maleate PO QD Monday through Friday. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.

ARM IV: Patients receive cediranib maleate PO QD on days 1-28 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.

After completion of study treatment, patients are followed up periodically for up to 5 years.

Typ studie

Intervenční

Zápis (Aktuální)

120

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Portoriko
      • Bayamón, Portoriko, 00959-5060
        • Cancer Center-Metro Medical Center Bayamon
      • Caguas, Portoriko, 00726
        • HIMA San Pablo Oncologic Hospital
      • Manati, Portoriko, 00674
        • Doctors Cancer Center
      • Ponce, Portoriko, 00716
        • Instituto Oncologia Moderna Ponce
      • San Juan, Portoriko, 00917
        • San Juan Community Oncology Group
      • San Juan, Portoriko, 00927
        • Centro Comprensivo de Cancer de UPR
      • San Juan, Portoriko, 00936
        • San Juan City Hospital
  • Spojené státy
    • Alaska
      • Anchorage, Alaska, Spojené státy, 98508
        • Anchorage Associates in Radiation Medicine
      • Anchorage, Alaska, Spojené státy, 99508
        • Alaska Breast Care and Surgery LLC
      • Anchorage, Alaska, Spojené státy, 99508
        • Alaska Oncology and Hematology LLC
      • Anchorage, Alaska, Spojené státy, 99508
        • Alaska Women's Cancer Care
      • Anchorage, Alaska, Spojené státy, 99508
        • Anchorage Oncology Centre
      • Anchorage, Alaska, Spojené státy, 99508
        • Katmai Oncology Group
      • Anchorage, Alaska, Spojené státy, 99508
        • Providence Alaska Medical Center
      • Anchorage, Alaska, Spojené státy, 99504
        • Anchorage Radiation Therapy Center
      • Fairbanks, Alaska, Spojené státy, 99701
        • Fairbanks Memorial Hospital
    • Arizona
      • Goodyear, Arizona, Spojené státy, 85338
        • CTCA at Western Regional Medical Center
      • Phoenix, Arizona, Spojené státy, 85004
        • Cancer Center at Saint Joseph's
    • Arkansas
      • Fort Smith, Arkansas, Spojené státy, 72903
        • Mercy Hospital Fort Smith
      • Hot Springs, Arkansas, Spojené státy, 71913
        • CHI Saint Vincent Cancer Center Hot Springs
      • Little Rock, Arkansas, Spojené státy, 72205
        • University of Arkansas for Medical Sciences
    • California
      • Arroyo Grande, California, Spojené státy, 93420
        • Mission Hope Medical Oncology - Arroyo Grande
      • Auburn, California, Spojené státy, 95602
        • Sutter Auburn Faith Hospital
      • Auburn, California, Spojené státy, 95603
        • Sutter Cancer Centers Radiation Oncology Services-Auburn
      • Berkeley, California, Spojené státy, 94704
        • Alta Bates Summit Medical Center-Herrick Campus
      • Burbank, California, Spojené státy, 91505
        • Providence Saint Joseph Medical Center/Disney Family Cancer Center
      • Cameron Park, California, Spojené státy, 95682
        • Sutter Cancer Centers Radiation Oncology Services-Cameron Park
      • Castro Valley, California, Spojené státy, 94546
        • Eden Hospital Medical Center
      • Concord, California, Spojené státy, 94520
        • John Muir Medical Center-Concord
      • Davis, California, Spojené státy, 95616
        • Sutter Davis Hospital
      • Duarte, California, Spojené státy, 91010
        • City of Hope Comprehensive Cancer Center
      • Fremont, California, Spojené státy, 94538
        • Palo Alto Medical Foundation-Fremont
      • Lancaster, California, Spojené státy, 93534
        • City of Hope Antelope Valley
      • Los Angeles, California, Spojené státy, 90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles, California, Spojené státy, 90033
        • Los Angeles General Medical Center
      • Modesto, California, Spojené státy, 95355
        • Memorial Medical Center
      • Mountain View, California, Spojené státy, 94040
        • Palo Alto Medical Foundation-Camino Division
      • Mountain View, California, Spojené státy, 94040
        • Palo Alto Medical Foundation-Gynecologic Oncology
      • Palo Alto, California, Spojené státy, 94301
        • Palo Alto Medical Foundation Health Care
      • Roseville, California, Spojené státy, 95661
        • Sutter Cancer Centers Radiation Oncology Services-Roseville
      • Roseville, California, Spojené státy, 95661
        • Sutter Roseville Medical Center
      • Sacramento, California, Spojené státy, 95816
        • Sutter Medical Center Sacramento
      • San Francisco, California, Spojené státy, 94115
        • California Pacific Medical Center-Pacific Campus
      • San Luis Obispo, California, Spojené státy, 93401
        • Pacific Central Coast Health Center-San Luis Obispo
      • Santa Cruz, California, Spojené státy, 95065
        • Palo Alto Medical Foundation-Santa Cruz
      • Santa Maria, California, Spojené státy, 93444
        • Mission Hope Medical Oncology - Santa Maria
      • Santa Rosa, California, Spojené státy, 95403
        • Sutter Pacific Medical Foundation
      • South Pasadena, California, Spojené státy, 91030
        • City of Hope South Pasadena
      • Sunnyvale, California, Spojené státy, 94086
        • Palo Alto Medical Foundation-Sunnyvale
      • Upland, California, Spojené státy, 91786
        • City of Hope Upland
      • Vallejo, California, Spojené státy, 94589
        • Sutter Solano Medical Center/Cancer Center
      • Walnut Creek, California, Spojené státy, 94598
        • John Muir Medical Center-Walnut Creek
    • Colorado
      • Aurora, Colorado, Spojené státy, 80012
        • Rocky Mountain Cancer Centers-Aurora
      • Boulder, Colorado, Spojené státy, 80304
        • Rocky Mountain Cancer Centers-Boulder
      • Centennial, Colorado, Spojené státy, 80112
        • Rocky Mountain Cancer Centers - Centennial
      • Colorado Springs, Colorado, Spojené státy, 80907
        • Penrose-Saint Francis Healthcare
      • Colorado Springs, Colorado, Spojené státy, 80907
        • Rocky Mountain Cancer Centers-Penrose
      • Denver, Colorado, Spojené státy, 80210
        • AdventHealth Porter
      • Durango, Colorado, Spojené státy, 81301
        • Mercy Medical Center
      • Durango, Colorado, Spojené státy, 81301
        • CommonSpirit Cancer Center Mercy
      • Lakewood, Colorado, Spojené státy, 80228
        • CommonSpirit Saint Anthony Hospital Cancer Center
      • Littleton, Colorado, Spojené státy, 80120
        • Rocky Mountain Cancer Centers-Littleton
      • Littleton, Colorado, Spojené státy, 80122
        • AdventHealth Littleton
      • Lone Tree, Colorado, Spojené státy, 80124
        • Rocky Mountain Cancer Centers-Sky Ridge
      • Longmont, Colorado, Spojené státy, 80501
        • Longmont United Hospital
      • Longmont, Colorado, Spojené státy, 80501
        • Rocky Mountain Cancer Centers-Longmont
      • Loveland, Colorado, Spojené státy, 80539
        • Banner North Colorado Medical Center - Loveland Campus
      • Parker, Colorado, Spojené státy, 80138
        • AdventHealth Parker
      • Pueblo, Colorado, Spojené státy, 81004
        • Saint Mary Corwin Medical Center
    • Connecticut
      • Danbury, Connecticut, Spojené státy, 06810
        • Danbury Hospital
      • Norwalk, Connecticut, Spojené státy, 06856
        • Norwalk Hospital
    • Florida
      • Pensacola, Florida, Spojené státy, 32504
        • Sacred Heart Hospital
    • Georgia
      • Atlanta, Georgia, Spojené státy, 30342
        • Northside Hospital
      • Newnan, Georgia, Spojené státy, 30265
        • CTCA at Southeastern Regional Medical Center
    • Hawaii
      • Honolulu, Hawaii, Spojené státy, 96813
        • Queen's Medical Center
      • Honolulu, Hawaii, Spojené státy, 96826
        • Kapiolani Medical Center for Women and Children
    • Idaho
      • Boise, Idaho, Spojené státy, 83706
        • Saint Alphonsus Cancer Care Center-Boise
      • Boise, Idaho, Spojené státy, 83712
        • Saint Luke's Cancer Institute - Boise
      • Caldwell, Idaho, Spojené státy, 83605
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, Spojené státy, 83814
        • Kootenai Health - Coeur d'Alene
      • Emmett, Idaho, Spojené státy, 83617
        • Walter Knox Memorial Hospital
      • Fruitland, Idaho, Spojené státy, 83619
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian, Idaho, Spojené státy, 83642
        • Idaho Urologic Institute-Meridian
      • Meridian, Idaho, Spojené státy, 83642
        • Saint Luke's Cancer Institute - Meridian
      • Nampa, Idaho, Spojené státy, 83687
        • Saint Alphonsus Cancer Care Center-Nampa
      • Nampa, Idaho, Spojené státy, 83687
        • Saint Luke's Cancer Institute - Nampa
      • Post Falls, Idaho, Spojené státy, 83854
        • Kootenai Clinic Cancer Services - Post Falls
      • Sandpoint, Idaho, Spojené státy, 83864
        • Kootenai Clinic Cancer Services - Sandpoint
      • Twin Falls, Idaho, Spojené státy, 83301
        • Saint Luke's Cancer Institute - Twin Falls
    • Illinois
      • Alton, Illinois, Spojené státy, 62002
        • OSF Saint Anthony's Health Center
      • Aurora, Illinois, Spojené státy, 60504
        • Rush-Copley Medical Center
      • Bloomington, Illinois, Spojené státy, 61704
        • Illinois CancerCare-Bloomington
      • Canton, Illinois, Spojené státy, 61520
        • Illinois CancerCare-Canton
      • Carbondale, Illinois, Spojené státy, 62902
        • Memorial Hospital of Carbondale
      • Carterville, Illinois, Spojené státy, 62918
        • SIH Cancer Institute
      • Carthage, Illinois, Spojené státy, 62321
        • Illinois CancerCare-Carthage
      • Centralia, Illinois, Spojené státy, 62801
        • Centralia Oncology Clinic
      • Chicago, Illinois, Spojené státy, 60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago, Illinois, Spojené státy, 60612
        • John H Stroger Jr Hospital of Cook County
      • Chicago, Illinois, Spojené státy, 60612
        • Rush MD Anderson Cancer Center
      • Danville, Illinois, Spojené státy, 61832
        • Carle at The Riverfront
      • Decatur, Illinois, Spojené státy, 62526
        • Decatur Memorial Hospital
      • Decatur, Illinois, Spojené státy, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Dixon, Illinois, Spojené státy, 61021
        • Illinois CancerCare-Dixon
      • Effingham, Illinois, Spojené státy, 62401
        • Crossroads Cancer Center
      • Effingham, Illinois, Spojené státy, 62401
        • Carle Physician Group-Effingham
      • Eureka, Illinois, Spojené státy, 61530
        • Illinois CancerCare-Eureka
      • Evanston, Illinois, Spojené státy, 60201
        • NorthShore University HealthSystem-Evanston Hospital
      • Galesburg, Illinois, Spojené státy, 61401
        • Western Illinois Cancer Treatment Center
      • Galesburg, Illinois, Spojené státy, 61401
        • Illinois CancerCare-Galesburg
      • Geneva, Illinois, Spojené státy, 60134
        • Northwestern Medicine Cancer Center Delnor
      • Glenview, Illinois, Spojené státy, 60026
        • NorthShore University HealthSystem-Glenbrook Hospital
      • Harvey, Illinois, Spojené státy, 60426
        • Ingalls Memorial Hospital
      • Highland Park, Illinois, Spojené státy, 60035
        • NorthShore University HealthSystem-Highland Park Hospital
      • Hinsdale, Illinois, Spojené státy, 60521
        • Sudarshan K Sharma MD Limited-Gynecologic Oncology
      • Kewanee, Illinois, Spojené státy, 61443
        • Illinois CancerCare-Kewanee Clinic
      • Macomb, Illinois, Spojené státy, 61455
        • Illinois CancerCare-Macomb
      • Mattoon, Illinois, Spojené státy, 61938
        • Carle Physician Group-Mattoon/Charleston
      • Mount Vernon, Illinois, Spojené státy, 62864
        • SSM Health Good Samaritan
      • New Lenox, Illinois, Spojené státy, 60451
        • UC Comprehensive Cancer Center at Silver Cross
      • O'Fallon, Illinois, Spojené státy, 62269
        • Cancer Care Center of O'Fallon
      • Orland Park, Illinois, Spojené státy, 60462
        • University of Chicago Medicine-Orland Park
      • Ottawa, Illinois, Spojené státy, 61350
        • Illinois CancerCare-Ottawa Clinic
      • Pekin, Illinois, Spojené státy, 61554
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, Spojené státy, 61636
        • Methodist Medical Center of Illinois
      • Peoria, Illinois, Spojené státy, 61615
        • Illinois CancerCare-Peoria
      • Peru, Illinois, Spojené státy, 61354
        • Illinois CancerCare-Peru
      • Peru, Illinois, Spojené státy, 61354
        • Valley Radiation Oncology
      • Princeton, Illinois, Spojené státy, 61356
        • Illinois CancerCare-Princeton
      • Springfield, Illinois, Spojené státy, 62702
        • Southern Illinois University School of Medicine
      • Springfield, Illinois, Spojené státy, 62702
        • Springfield Clinic
      • Springfield, Illinois, Spojené státy, 62781
        • Springfield Memorial Hospital
      • Urbana, Illinois, Spojené státy, 61801
        • Carle Cancer Center
      • Urbana, Illinois, Spojené státy, 61801
        • The Carle Foundation Hospital
      • Warrenville, Illinois, Spojené státy, 60555
        • Northwestern Medicine Cancer Center Warrenville
      • Washington, Illinois, Spojené státy, 61571
        • Illinois CancerCare - Washington
      • Yorkville, Illinois, Spojené státy, 60560
        • Rush-Copley Healthcare Center
      • Zion, Illinois, Spojené státy, 60099
        • Midwestern Regional Medical Center
    • Indiana
      • South Bend, Indiana, Spojené státy, 46601
        • Memorial Hospital of South Bend
    • Iowa
      • Ames, Iowa, Spojené státy, 50010
        • Mary Greeley Medical Center
      • Ames, Iowa, Spojené státy, 50010
        • McFarland Clinic - Ames
      • Boone, Iowa, Spojené státy, 50036
        • McFarland Clinic - Boone
      • Cedar Rapids, Iowa, Spojené státy, 52403
        • Mercy Hospital
      • Cedar Rapids, Iowa, Spojené státy, 52403
        • Oncology Associates at Mercy Medical Center
      • Clive, Iowa, Spojené státy, 50325
        • Mercy Cancer Center-West Lakes
      • Clive, Iowa, Spojené státy, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Council Bluffs, Iowa, Spojené státy, 51503
        • Alegent Health Mercy Hospital
      • Creston, Iowa, Spojené státy, 50801
        • Greater Regional Medical Center
      • Des Moines, Iowa, Spojené státy, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, Spojené státy, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Fort Dodge, Iowa, Spojené státy, 50501
        • McFarland Clinic - Trinity Cancer Center
      • Iowa City, Iowa, Spojené státy, 52242
        • University of Iowa/Holden Comprehensive Cancer Center
      • Jefferson, Iowa, Spojené státy, 50129
        • McFarland Clinic - Jefferson
      • Marshalltown, Iowa, Spojené státy, 50158
        • McFarland Clinic - Marshalltown
      • West Des Moines, Iowa, Spojené státy, 50266
        • Mercy Medical Center-West Lakes
    • Kansas
      • Garden City, Kansas, Spojené státy, 67846
        • Central Care Cancer Center - Garden City
      • Great Bend, Kansas, Spojené státy, 67530
        • Central Care Cancer Center - Great Bend
    • Kentucky
      • Bardstown, Kentucky, Spojené státy, 40004
        • CommonSpirit Saint Joseph Hospital - Bardstown
      • Corbin, Kentucky, Spojené státy, 40701
        • Commonwealth Cancer Center-Corbin
      • Lexington, Kentucky, Spojené státy, 40504
        • Saint Joseph Radiation Oncology Resource Center
      • Lexington, Kentucky, Spojené státy, 40509
        • CommonSpirit Saint Joseph Medical Center - East Lexington
      • London, Kentucky, Spojené státy, 40741
        • CommonSpirit Saint Joseph Hospital London
      • Louisville, Kentucky, Spojené státy, 40202
        • Jewish Hospital
      • Louisville, Kentucky, Spojené státy, 40245
        • UofL Health Medical Center Northeast
      • Louisville, Kentucky, Spojené státy, 40215
        • Saints Mary and Elizabeth Hospital
      • Shepherdsville, Kentucky, Spojené státy, 40165
        • Jewish Hospital Medical Center South
    • Louisiana
      • Baton Rouge, Louisiana, Spojené státy, 70817
        • Our Lady of the Lake Medical Oncology
    • Maine
      • Augusta, Maine, Spojené státy, 04330
        • Harold Alfond Center for Cancer Care
      • Brewer, Maine, Spojené státy, 04412
        • Lafayette Family Cancer Center-EMMC
      • Scarborough, Maine, Spojené státy, 04074
        • MaineHealth Maine Medical Center- Scarborough
    • Maryland
      • Baltimore, Maryland, Spojené státy, 21204
        • Greater Baltimore Medical Center
      • Bethesda, Maryland, Spojené státy, 20892
        • National Institutes of Health Clinical Center
    • Michigan
      • Ann Arbor, Michigan, Spojené státy, 48109
        • University of Michigan Rogel Cancer Center
      • Dearborn, Michigan, Spojené státy, 48124
        • Corewell Health Dearborn Hospital
      • Royal Oak, Michigan, Spojené státy, 48073
        • Corewell Health William Beaumont University Hospital
      • Troy, Michigan, Spojené státy, 48085
        • Corewell Health Beaumont Troy Hospital
    • Minnesota
      • Burnsville, Minnesota, Spojené státy, 55337
        • Fairview Ridges Hospital
      • Burnsville, Minnesota, Spojené státy, 55337
        • Minnesota Oncology - Burnsville
      • Cambridge, Minnesota, Spojené státy, 55008
        • Cambridge Medical Center
      • Coon Rapids, Minnesota, Spojené státy, 55433
        • Mercy Hospital
      • Edina, Minnesota, Spojené státy, 55435
        • Fairview Southdale Hospital
      • Fridley, Minnesota, Spojené státy, 55432
        • Unity Hospital
      • Maple Grove, Minnesota, Spojené státy, 55369
        • Fairview Clinics and Surgery Center Maple Grove
      • Maplewood, Minnesota, Spojené státy, 55109
        • Saint John's Hospital - Healtheast
      • Maplewood, Minnesota, Spojené státy, 55109
        • Minnesota Oncology Hematology PA-Maplewood
      • Minneapolis, Minnesota, Spojené státy, 55415
        • Hennepin County Medical Center
      • Minneapolis, Minnesota, Spojené státy, 55407
        • Abbott-Northwestern Hospital
      • Minneapolis, Minnesota, Spojené státy, 55454
        • Health Partners Inc
      • Minneapolis, Minnesota, Spojené státy, 55455
        • University of Minnesota/Masonic Cancer Center
      • Monticello, Minnesota, Spojené státy, 55362
        • Monticello Cancer Center
      • New Ulm, Minnesota, Spojené státy, 56073
        • New Ulm Medical Center
      • Princeton, Minnesota, Spojené státy, 55371
        • Fairview Northland Medical Center
      • Robbinsdale, Minnesota, Spojené státy, 55422
        • North Memorial Medical Health Center
      • Saint Louis Park, Minnesota, Spojené státy, 55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Paul, Minnesota, Spojené státy, 55101
        • Regions Hospital
      • Saint Paul, Minnesota, Spojené státy, 55102
        • United Hospital
      • Shakopee, Minnesota, Spojené státy, 55379
        • Saint Francis Regional Medical Center
      • Stillwater, Minnesota, Spojené státy, 55082
        • Lakeview Hospital
      • Waconia, Minnesota, Spojené státy, 55387
        • Ridgeview Medical Center
      • Willmar, Minnesota, Spojené státy, 56201
        • Rice Memorial Hospital
      • Woodbury, Minnesota, Spojené státy, 55125
        • Minnesota Oncology Hematology PA-Woodbury
      • Wyoming, Minnesota, Spojené státy, 55092
        • Fairview Lakes Medical Center
    • Missouri
      • Ballwin, Missouri, Spojené státy, 63011
        • Mercy Oncology and Hematology - Clayton-Clarkson
      • Bolivar, Missouri, Spojené státy, 65613
        • Central Care Cancer Center - Bolivar
      • Cape Girardeau, Missouri, Spojené státy, 63703
        • Saint Francis Medical Center
      • Cape Girardeau, Missouri, Spojené státy, 63703
        • Mercy Cancer Center - Cape Girardeau
      • Farmington, Missouri, Spojené státy, 63640
        • Parkland Health Center - Farmington
      • Jefferson City, Missouri, Spojené státy, 65109
        • MU Health Care Goldschmidt Cancer Center
      • Joplin, Missouri, Spojené státy, 64804
        • Freeman Health System
      • Joplin, Missouri, Spojené státy, 64804
        • Mercy Hospital Joplin
      • Rolla, Missouri, Spojené státy, 65401
        • Mercy Clinic-Rolla-Cancer and Hematology
      • Rolla, Missouri, Spojené státy, 65401
        • Phelps Health Delbert Day Cancer Institute
      • Saint Joseph, Missouri, Spojené státy, 64506
        • Heartland Regional Medical Center
      • Sainte Genevieve, Missouri, Spojené státy, 63670
        • Sainte Genevieve County Memorial Hospital
      • Springfield, Missouri, Spojené státy, 65807
        • CoxHealth South Hospital
      • Springfield, Missouri, Spojené státy, 65804
        • Mercy Hospital Springfield
      • St Louis, Missouri, Spojené státy, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Spojené státy, 63131
        • Missouri Baptist Medical Center
      • St Louis, Missouri, Spojené státy, 63109
        • Mercy Infusion Center - Chippewa
      • St Louis, Missouri, Spojené státy, 63141
        • Mercy Hospital Saint Louis
      • St Louis, Missouri, Spojené státy, 63128
        • Mercy Hospital South
      • Sullivan, Missouri, Spojené státy, 63080
        • Missouri Baptist Sullivan Hospital
      • Washington, Missouri, Spojené státy, 63090
        • Mercy Hospital Washington
    • Montana
      • Anaconda, Montana, Spojené státy, 59711
        • Community Hospital of Anaconda
      • Billings, Montana, Spojené státy, 59101
        • Billings Clinic Cancer Center
      • Bozeman, Montana, Spojené státy, 59715
        • Bozeman Health Deaconess Hospital
      • Great Falls, Montana, Spojené státy, 59405
        • Great Falls Clinic
      • Great Falls, Montana, Spojené státy, 59405
        • Benefis Sletten Cancer Institute
      • Kalispell, Montana, Spojené státy, 59901
        • Logan Health Medical Center
      • Missoula, Montana, Spojené státy, 59802
        • Saint Patrick Hospital - Community Hospital
      • Missoula, Montana, Spojené státy, 59804
        • Community Medical Center
    • Nebraska
      • Grand Island, Nebraska, Spojené státy, 68803
        • Nebraska Cancer Specialists/Oncology Hematology West PC
      • Kearney, Nebraska, Spojené státy, 68847
        • CHI Health Good Samaritan
      • Lincoln, Nebraska, Spojené státy, 68510
        • Saint Elizabeth Regional Medical Center
      • Lincoln, Nebraska, Spojené státy, 68516
        • Cancer Partners of Nebraska
      • Omaha, Nebraska, Spojené státy, 68114
        • Nebraska Methodist Hospital
      • Omaha, Nebraska, Spojené státy, 68198
        • University of Nebraska Medical Center
      • Omaha, Nebraska, Spojené státy, 68124
        • Alegent Health Bergan Mercy Medical Center
      • Omaha, Nebraska, Spojené státy, 68122
        • Alegent Health Immanuel Medical Center
      • Omaha, Nebraska, Spojené státy, 68130
        • Alegent Health Lakeside Hospital
      • Papillion, Nebraska, Spojené státy, 68046
        • Midlands Community Hospital
    • Nevada
      • Las Vegas, Nevada, Spojené státy, 89106
        • Women's Cancer Center of Nevada
    • New Jersey
      • Neptune City, New Jersey, Spojené státy, 07753
        • Jersey Shore Medical Center
    • New Mexico
      • Albuquerque, New Mexico, Spojené státy, 87106
        • University of New Mexico Cancer Center
      • Las Cruces, New Mexico, Spojené státy, 88011
        • Memorial Medical Center-Las Cruces
      • Rio Rancho, New Mexico, Spojené státy, 87124
        • Presbyterian Rust Medical Center/Jorgensen Cancer Center
    • New York
      • Bay Shore, New York, Spojené státy, 11706
        • Northwell Health Imbert Cancer Center
      • Brightwaters, New York, Spojené státy, 11718
        • Island Gynecologic Oncology
      • Buffalo, New York, Spojené státy, 14263
        • Roswell Park Cancer Institute
      • Lake Success, New York, Spojené státy, 11042
        • Northwell Health/Center for Advanced Medicine
      • Syracuse, New York, Spojené státy, 13210
        • State University of New York Upstate Medical University
      • White Plains, New York, Spojené státy, 10601
        • Dickstein Cancer Treatment Center
    • North Carolina
      • Clinton, North Carolina, Spojené státy, 28328
        • Southeastern Medical Oncology Center-Clinton
      • Goldsboro, North Carolina, Spojené státy, 27534
        • Southeastern Medical Oncology Center-Goldsboro
      • Jacksonville, North Carolina, Spojené státy, 28546
        • Southeastern Medical Oncology Center-Jacksonville
    • Ohio
      • Akron, Ohio, Spojené státy, 44304
        • Summa Health System - Akron Campus
      • Alliance, Ohio, Spojené státy, 44601
        • Aultman Alliance Community Hospital
      • Beachwood, Ohio, Spojené státy, 44122
        • UHHS-Chagrin Highlands Medical Center
      • Belpre, Ohio, Spojené státy, 45714
        • Strecker Cancer Center-Belpre
      • Canton, Ohio, Spojené státy, 44710
        • Aultman Health Foundation
      • Centerville, Ohio, Spojené státy, 45459
        • Miami Valley Hospital South
      • Chardon, Ohio, Spojené státy, 44024
        • Geauga Hospital
      • Chillicothe, Ohio, Spojené státy, 45601
        • Adena Regional Medical Center
      • Cincinnati, Ohio, Spojené státy, 45220
        • Good Samaritan Hospital - Cincinnati
      • Cincinnati, Ohio, Spojené státy, 45242
        • Bethesda North Hospital
      • Cincinnati, Ohio, Spojené státy, 45247
        • TriHealth Cancer Institute-Westside
      • Cincinnati, Ohio, Spojené státy, 45255
        • TriHealth Cancer Institute-Anderson
      • Cleveland, Ohio, Spojené státy, 44106
        • Case Western Reserve University
      • Cleveland, Ohio, Spojené státy, 44195
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, Spojené státy, 44111
        • Cleveland Clinic Cancer Center/Fairview Hospital
      • Columbus, Ohio, Spojené státy, 43214
        • Riverside Methodist Hospital
      • Columbus, Ohio, Spojené státy, 43210
        • Ohio State University Comprehensive Cancer Center
      • Columbus, Ohio, Spojené státy, 43219
        • The Mark H Zangmeister Center
      • Columbus, Ohio, Spojené státy, 43214
        • Columbus Oncology and Hematology Associates Inc
      • Columbus, Ohio, Spojené státy, 43228
        • Doctors Hospital
      • Columbus, Ohio, Spojené státy, 43213
        • Mount Carmel East Hospital
      • Columbus, Ohio, Spojené státy, 43215
        • Grant Medical Center
      • Columbus, Ohio, Spojené státy, 43222
        • Mount Carmel Health Center West
      • Dayton, Ohio, Spojené státy, 45409
        • Miami Valley Hospital
      • Delaware, Ohio, Spojené státy, 43015
        • Delaware Health Center-Grady Cancer Center
      • Delaware, Ohio, Spojené státy, 43015
        • Grady Memorial Hospital
      • Dublin, Ohio, Spojené státy, 43016
        • Dublin Methodist Hospital
      • Gahanna, Ohio, Spojené státy, 43230
        • Central Ohio Breast and Endocrine Surgery
      • Grove City, Ohio, Spojené státy, 43123
        • Mount Carmel Grove City Hospital
      • Lancaster, Ohio, Spojené státy, 43130
        • Fairfield Medical Center
      • Lima, Ohio, Spojené státy, 45801
        • Saint Rita's Medical Center
      • Mansfield, Ohio, Spojené státy, 44903
        • OhioHealth Mansfield Hospital
      • Marietta, Ohio, Spojené státy, 45750
        • Marietta Memorial Hospital
      • Marion, Ohio, Spojené státy, 43302
        • OhioHealth Marion General Hospital
      • Mayfield Heights, Ohio, Spojené státy, 44124
        • Hillcrest Hospital Cancer Center
      • Mentor, Ohio, Spojené státy, 44060
        • UH Seidman Cancer Center at Lake Health Mentor Campus
      • Mount Vernon, Ohio, Spojené státy, 43050
        • Knox Community Hospital
      • Newark, Ohio, Spojené státy, 43055
        • Licking Memorial Hospital
      • Newark, Ohio, Spojené státy, 43055
        • Newark Radiation Oncology
      • Perrysburg, Ohio, Spojené státy, 43551
        • Mercy Health - Perrysburg Hospital
      • Portsmouth, Ohio, Spojené státy, 45662
        • Southern Ohio Medical Center
      • Toledo, Ohio, Spojené státy, 43623
        • Mercy Health - Saint Anne Hospital
      • Toledo, Ohio, Spojené státy, 43608
        • Mercy Health - Saint Vincent Hospital
      • Wadsworth, Ohio, Spojené státy, 44281
        • University Hospitals Sharon Health Center
      • Westerville, Ohio, Spojené státy, 43081
        • Saint Ann's Hospital
      • Westlake, Ohio, Spojené státy, 44145
        • UH Seidman Cancer Center at Saint John Medical Center
      • Zanesville, Ohio, Spojené státy, 43701
        • Genesis Healthcare System Cancer Care Center
    • Oklahoma
      • Lawton, Oklahoma, Spojené státy, 73505
        • Cancer Centers of Southwest Oklahoma Research
      • Oklahoma City, Oklahoma, Spojené státy, 73104
        • University of Oklahoma Health Sciences Center
      • Oklahoma City, Oklahoma, Spojené státy, 73120
        • Mercy Hospital Oklahoma City
      • Tulsa, Oklahoma, Spojené státy, 74146
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
    • Oregon
      • Baker City, Oregon, Spojené státy, 97814
        • Saint Alphonsus Cancer Care Center-Baker City
      • Bend, Oregon, Spojené státy, 97701
        • Saint Charles Health System
      • Clackamas, Oregon, Spojené státy, 97015
        • Clackamas Radiation Oncology Center
      • Clackamas, Oregon, Spojené státy, 97015
        • Providence Cancer Institute Clackamas Clinic
      • Coos Bay, Oregon, Spojené státy, 97420
        • Bay Area Hospital
      • Newberg, Oregon, Spojené státy, 97132
        • Providence Newberg Medical Center
      • Ontario, Oregon, Spojené státy, 97914
        • Saint Alphonsus Cancer Care Center-Ontario
      • Portland, Oregon, Spojené státy, 97210
        • Legacy Good Samaritan Hospital and Medical Center
      • Portland, Oregon, Spojené státy, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, Spojené státy, 97225
        • Providence Saint Vincent Medical Center
      • Redmond, Oregon, Spojené státy, 97756
        • Saint Charles Health System-Redmond
      • Tualatin, Oregon, Spojené státy, 97062
        • Legacy Meridian Park Hospital
    • Pennsylvania
      • Butler, Pennsylvania, Spojené státy, 16001
        • UPMC Hillman Cancer Center at Butler Health System
      • Erie, Pennsylvania, Spojené státy, 16505
        • UPMC Hillman Cancer Center Erie
      • Paoli, Pennsylvania, Spojené státy, 19301
        • Paoli Memorial Hospital
      • Philadelphia, Pennsylvania, Spojené státy, 19107
        • Thomas Jefferson University Hospital
      • Philadelphia, Pennsylvania, Spojené státy, 19114
        • Jefferson Torresdale Hospital
      • Pittsburgh, Pennsylvania, Spojené státy, 15224
        • West Penn Hospital
      • Pittsburgh, Pennsylvania, Spojené státy, 15232
        • UPMC Hillman Cancer Center
      • Pittsburgh, Pennsylvania, Spojené státy, 15213
        • UPMC-Magee Womens Hospital
      • Pittsburgh, Pennsylvania, Spojené státy, 15237
        • UPMC-Passavant Hospital
      • Willow Grove, Pennsylvania, Spojené státy, 19090
        • Asplundh Cancer Pavilion
      • Wynnewood, Pennsylvania, Spojené státy, 19096
        • Lankenau Medical Center
    • Rhode Island
      • Providence, Rhode Island, Spojené státy, 02905
        • Women and Infants Hospital
    • South Carolina
      • Charleston, South Carolina, Spojené státy, 29425
        • Medical University of South Carolina
      • Greenville, South Carolina, Spojené státy, 29607
        • Saint Francis Cancer Center
      • Greenville, South Carolina, Spojené státy, 29601
        • Saint Francis Hospital
    • South Dakota
      • Rapid City, South Dakota, Spojené státy, 57701
        • Rapid City Regional Hospital
    • Tennessee
      • Bristol, Tennessee, Spojené státy, 37620
        • Bristol Regional Medical Center
      • Kingsport, Tennessee, Spojené státy, 37660
        • Ballad Health Cancer Care - Kingsport
      • Kingsport, Tennessee, Spojené státy, 37660
        • Wellmont Holston Valley Hospital and Medical Center
      • Knoxville, Tennessee, Spojené státy, 37916
        • Covenant Health Cancer Centers
      • Knoxville, Tennessee, Spojené státy, 37932
        • Covenant Health Cancer Centers - West
      • Nashville, Tennessee, Spojené státy, 37232
        • Vanderbilt University/Ingram Cancer Center
      • Nashville, Tennessee, Spojené státy, 37204
        • Vanderbilt Breast Center at One Hundred Oaks
    • Texas
      • Bryan, Texas, Spojené státy, 77802
        • Saint Joseph Regional Cancer Center
      • Dallas, Texas, Spojené státy, 75235
        • Parkland Memorial Hospital
      • Dallas, Texas, Spojené státy, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Houston, Texas, Spojené státy, 77030
        • Houston Methodist Hospital
      • Houston, Texas, Spojené státy, 77070
        • Methodist Willowbrook Hospital
      • Houston, Texas, Spojené státy, 77094
        • Houston Methodist West Hospital
      • Sugar Land, Texas, Spojené státy, 77479
        • Houston Methodist Sugar Land Hospital
      • The Woodlands, Texas, Spojené státy, 77385
        • Houston Methodist The Woodlands Hospital
    • Virginia
      • Bristol, Virginia, Spojené státy, 24201
        • Ballad Health Cancer Care - Bristol
      • Norton, Virginia, Spojené státy, 24273
        • Ballad Health Cancer Care - Norton
    • Washington
      • Aberdeen, Washington, Spojené státy, 98520
        • Providence Regional Cancer System-Aberdeen
      • Bellingham, Washington, Spojené státy, 98225
        • PeaceHealth Saint Joseph Medical Center
      • Burien, Washington, Spojené státy, 98166
        • Saint Anne Hospital
      • Centralia, Washington, Spojené státy, 98531
        • Providence Regional Cancer System-Centralia
      • Edmonds, Washington, Spojené státy, 98026
        • Swedish Cancer Institute-Edmonds
      • Enumclaw, Washington, Spojené státy, 98022
        • Saint Elizabeth Hospital
      • Everett, Washington, Spojené státy, 98201
        • Providence Regional Cancer Partnership
      • Federal Way, Washington, Spojené státy, 98003
        • Saint Francis Hospital
      • Issaquah, Washington, Spojené státy, 98029
        • Swedish Cancer Institute-Issaquah
      • Kennewick, Washington, Spojené státy, 99336
        • Kadlec Clinic Hematology and Oncology
      • Lacey, Washington, Spojené státy, 98503
        • Providence Regional Cancer System-Lacey
      • Lakewood, Washington, Spojené státy, 98499
        • Saint Clare Hospital
      • Longview, Washington, Spojené státy, 98632
        • PeaceHealth Saint John Medical Center
      • Port Townsend, Washington, Spojené státy, 98368
        • Jefferson Healthcare
      • Seattle, Washington, Spojené státy, 98107
        • Swedish Medical Center-Ballard Campus
      • Seattle, Washington, Spojené státy, 98122
        • Swedish Medical Center-First Hill
      • Seattle, Washington, Spojené státy, 98104
        • Pacific Gynecology Specialists
      • Seattle, Washington, Spojené státy, 98122-5711
        • Swedish Medical Center-Cherry Hill
      • Sedro-Woolley, Washington, Spojené státy, 98284
        • PeaceHealth United General Medical Center
      • Shelton, Washington, Spojené státy, 98584
        • Providence Regional Cancer System-Shelton
      • Silverdale, Washington, Spojené státy, 98383
        • Saint Joseph Medical Center Hematology and Oncology - Silverdale
      • Tacoma, Washington, Spojené státy, 98405
        • Franciscan Research Center-Northwest Medical Plaza
      • Vancouver, Washington, Spojené státy, 98686
        • Legacy Salmon Creek Hospital
      • Vancouver, Washington, Spojené státy, 98664
        • PeaceHealth Southwest Medical Center
      • Walla Walla, Washington, Spojené státy, 99362
        • Providence Saint Mary Regional Cancer Center
      • Yelm, Washington, Spojené státy, 98597
        • Providence Regional Cancer System-Yelm
    • West Virginia
      • Charleston, West Virginia, Spojené státy, 25304
        • Vandalia Health/CAMC Institute for Academic Medicine
    • Wisconsin
      • Green Bay, Wisconsin, Spojené státy, 54301
        • Saint Vincent Hospital Cancer Center Green Bay
      • Green Bay, Wisconsin, Spojené státy, 54303
        • Saint Vincent Hospital Cancer Center at Saint Mary's
      • La Crosse, Wisconsin, Spojené státy, 54601
        • Gundersen Lutheran Medical Center
      • Milwaukee, Wisconsin, Spojené státy, 53226
        • Medical College of Wisconsin
      • Mukwonago, Wisconsin, Spojené státy, 53149
        • ProHealth D N Greenwald Center
      • New Richmond, Wisconsin, Spojené státy, 54017
        • Cancer Center of Western Wisconsin
      • Oconomowoc, Wisconsin, Spojené státy, 53066
        • ProHealth Oconomowoc Memorial Hospital
      • Oconto Falls, Wisconsin, Spojené státy, 54154
        • Saint Vincent Hospital Cancer Center at Oconto Falls
      • Sturgeon Bay, Wisconsin, Spojené státy, 54235-1495
        • Saint Vincent Hospital Cancer Center at Sturgeon Bay
      • Waukesha, Wisconsin, Spojené státy, 53188
        • UW Cancer Center at ProHealth Care
      • Waukesha, Wisconsin, Spojené státy, 53188
        • ProHealth Waukesha Memorial Hospital
    • Wyoming
      • Cody, Wyoming, Spojené státy, 82414
        • Billings Clinic-Cody
      • Sheridan, Wyoming, Spojené státy, 82801
        • Welch Cancer Center

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Ženský

Popis

Inclusion Criteria:

  • Women with recurrent/persistent platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers; platinum-resistant disease is defined as progression within < 6 months from completion of platinum based therapy. The date should be calculated from the last administered dose of platinum therapy

  • Patients must have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of high grade serous, grade 3 endometrioid or clear cell carcinoma based on local histopathological findings. Patients with low grade serous, grade 1 or 2 endometrioid, mixed epithelial, undifferentiated carcinoma, or mucinous carcinoma histologies are also eligible, provided that the patient has a known deleterious BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory. Histologic confirmation of the original primary tumor is required via the pathology report (upload of report required). Confirmation of BRCA1 and BRCA2 germline and/or somatic mutation status and hormone receptor (HR) status is required for all entered patients (if available) via testing report (upload of report[s] required)

  • Evaluable disease - defined as RECIST 1.1 measurable disease OR non-measurable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related in the setting of a CA125 >= 2 x upper limit of normal [ULN])

  • Prior therapy:

    • At least two prior treatment regimens (including primary therapy) but up to 5 lines of systemic anticancer therapy. Hormonal therapy (such as tamoxifen, aromatase inhibitors) will not count as a previous treatment regimen.
    • Prior use of bevacizumab in the upfront or recurrent setting is required.
    • Prior use of PARP inhibitor is allowed.
    • Prior use of immune checkpoint blockade (e.g., a PD-L1/PD-1inhibitor or a CTLA-4 inhibitor) is allowed

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

  • Absolute neutrophil count (ANC) >= 1,500/mcL

  • Hemoglobin >= 10 g/dL

  • Platelets >= 100,000/mcL

  • Creatinine clearance (CrCL) or estimated glomerular filtration rate (eGFR) of > 50 mL/min estimated using either the Cockcroft-Gault equation, the Modification of Diet in Renal Disease Study, or as reported in the comprehensive metabolic panel/basic metabolic panel (eGFR)

  • Urine protein: creatinine ratio (UPC) of =< 1

  • Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled)

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN

  • Age >= 18 years

  • Body weight > 30 kg

  • Adequately controlled blood pressure (systolic blood pressure [SBP] =< 140; diastolic blood pressure [DBP] =< 90 mmHg) on a maximum of three antihypertensive medications. Patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to study registration. It is strongly recommended that patients who are on three antihypertensive medications be followed by a cardiologist or a primary care physician for management of BP while on protocol. Patients must be willing and able to check and record daily blood pressure readings. BP cuffs will be provided to patients randomized to the cediranib-containing arms

  • Adequately controlled thyroid dysfunction with no symptoms of thyroid dysfunction and normal thyroid stimulating hormone (TSH). If TSH is not within normal range despite no symptoms of thyroid dysfunction, normal free T4 level is required

  • Able to swallow and retain oral medications and no gastrointestinal (GI) illnesses that would preclude absorption of olaparib and cediranib as judged by treating physician

  • Toxicities of prior therapy (excepting alopecia and vitiligo), should be resolved to less than or equal to grade 1 as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0

  • Women of childbearing potential (WOCBP) must agree to use two forms of birth control (hormonal or barrier method of birth control; abstinence). Note: Definition of women of no longer having childbearing potential: Postmenopausal or evidence of non-childbearing status for women of childbearing potential as confirmed by a negative urine or serum pregnancy test within 7 days prior to start of study treatment. Postmenopausal is defined as: Age >= 60 years, or age < 60 with any one or more of the conditions below:

    • Amenorrhoeic for >= 1 year in the absence of chemotherapy and/or hormonal treatments,
    • Luteinizing hormone and/or follicle stimulating hormone and/or estradiol levels in the post-menopausal range,
    • Radiation-induced oophorectomy with last menses > 1 year ago,
    • Chemotherapy-induced menopause with > 1 year interval since last menses,
    • Surgical sterilization (bilateral oophorectomy or hysterectomy)

  • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and authorization permitting release of personal health information

Exclusion Criteria:

  • Primary platinum-refractory disease defined as progression during first-line platinum-based chemotherapy

  • Rising CA-125 only without RECIST 1.1 evaluable disease

  • Prior therapy:

    • Patients who have had chemotherapy, investigational drugs or radiotherapy within 3 weeks prior to study registration or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier.

    • Patients may not have had hormonal therapy within 2 weeks of study registration. Patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions.

    • Prior use of concurrent olaparib and cediranib combination.

    • Patients who have experienced immune-mediated adverse events requiring dose modification or discontinuation.

    • For patients who have received prior PARP inhibitor:

      • Patients who have required dose modification or dose reduction of olaparib will not be eligible, as they will not be able to start this study at full dose.
      • Patients who have required dose reduction of non-olaparib PARP inhibitors for hematologic adverse events will not be eligible (Note: niraparib that is initiated at 200mg daily per weight and platelet guidelines is not considered a dose reduction).
      • Patients who required dose-reduction of non-olaparib PARP inhibitors for non-hematologic adverse events may be eligible after discussion with the Study Chair if the treating investigator feels that they could appropriately receive olaparib at full dose.

  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 3 months prior to study registration

  • Current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months of study registration except temporary (< 24 hr) improved with medical management, within last 3 months

  • Any prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1

  • Dependency on IV hydration or total parenteral nutrition (TPN)

  • Pregnant women. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with these drugs, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans should not be included on this study, since neurologic dysfunction may confound the evaluation of neurologic and other adverse events. Patients with treated brain metastases and resolution of any associated symptoms must demonstrate stable post-therapeutic imaging for at least 6 months following therapy prior to starting study registration

  • Patients who have the following clinical conditions are considered to be at increased risk for cardiac toxicities. Patients with any cardiac history of the following conditions:

    • History of myocardial infarction or myocarditis within six months of study registration
    • Unstable angina
    • Resting electrocardiogram (ECG) with clinically significant abnormal findings.
    • New York Heart Association functional classification of III or IV

  • If cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines. Patients with the following risk factors should have a baseline cardiac function assessment:

    • Prior treatment with anthracyclines
    • Prior treatment with trastuzumab or T-DM1
    • Prior central thoracic radiation therapy (RT), including RT to the heart
    • History of myocardial infarction within 6 to 12 months (Patients with history of myocardial infarction within 6 months are excluded from the study)
    • Prior history of impaired cardiac function

  • History of stroke or transient ischemic attack within six months of study registration

  • Clinically significant peripheral vascular disease or vascular disease (aortic aneurysm or aortic dissection)

  • Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study treatment. Patients must have recovered from any effects of any major surgery and surgical wound should have healed prior to starting treatment. Note: Local surgery of isolated lesions for palliative intent is acceptable

  • Evidence of coagulopathy or bleeding diathesis. Therapeutic anticoagulation for prior thromboembolic events, including warfarin, is permitted. Patients receiving warfarin are recommended to have careful monitoring of international normalized ratio (INR)

  • Evidence suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated. No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUBCT)

  • Human immunodeficiency virus (HIV) positive patients due to potential drug and drug interactions

  • Patients may not use any complementary or alternative medicines including natural herbal products or folk remedies as they may interfere with the effectiveness of the study treatments

  • Receipt of live attenuated vaccine within 30 days prior to the first dose of study treatment. Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to 30 days after the last dose of study treatment

  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation with controlled ventricular rate), or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring adverse events or compromise the ability of the patient to given written informed consent

  • Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4. Dihydropyridine calcium-channel blockers are permitted for management of hypertension

  • Current or prior use of immunosuppressive medication within 14 days of study registration. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
    • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab, olaparib, or cediranib

  • Patients with active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment

  • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis [TB] testing in line with local practice), hepatitis B (known positive hepatitis B virus [HBV] surface antigen (HBsAg) result), or hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for hepatitis C virus (HCV) ribonucleic acid (RNA)

  • Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: Arm I (paclitaxel, doxorubicin, topotecan hydrochloride))

Patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15, or pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8 and 15 or days 1-5 per the discretion of the treating physician. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
Lék: Paclitaxel

Given IV

Ostatní jména:
  • Taxol
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol Konzentrat
Postup: Computed Tomography

Undergo CT

Ostatní jména:
  • ČT
  • KOČKA
  • CAT skenování
  • Počítačová axiální tomografie
  • Počítačová tomografie
  • CT vyšetření
  • tomografie
  • Počítačová axiální tomografie (postup)
  • Počítačová tomografie (CT).
  • Diagnostické skenování CAT
  • Typ služby diagnostického skenování CAT
Postup: Magnetic Resonance Imaging

Undergo MRI

Ostatní jména:
  • MRI
  • Magnetická rezonance
  • Skenování magnetickou rezonancí
  • Lékařské zobrazování, magnetická rezonance / nukleární magnetická rezonance
  • PAN
  • MR zobrazování
  • MRI skenování
  • NMR zobrazování
  • NMRI
  • Nukleární magnetická rezonance
  • Zobrazování magnetickou rezonancí (MRI)
  • sMRI
  • Magnetická rezonance (postup)
  • Strukturální MRI
Postup: Echocardiography Test

Undergo ECHO

Ostatní jména:
  • Echokardiografie
  • EC
Postup: Multigated Acquisition Scan

Undergo MUGA

Ostatní jména:
  • Skenování bazénu krve
  • Rovnovážná radionuklidová angiografie
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklidová ventrikulografie
  • RNVG
  • Skenování SYMA
  • Synchronizované multigated Acquisition Scanning
  • Skenování MUGA
  • Multi-Gated Acquisition Scan
  • Radionuklidový Ventrikulogram Scan
  • Gated Heart Pool Scan
  • Skenování RNV
Postup: Biospecimen Collection

Undergo collection of blood

Ostatní jména:
  • Sběr biologických vzorků
  • Odebrán biovzorek
  • Sbírka vzorků
Lék: Pegylated Liposomal Doxorubicin Hydrochloride

Given IV

Ostatní jména:
  • ATI-0918
  • Caelyx
  • Doxil
  • Doxilen
  • Lipozom doxorubicin HCl
  • Duomeisu
  • Evacet
  • LipoDox
  • Liposomální adriamycin
  • Liposomálně zapouzdřený doxorubicin
  • Pegylovaný doxorubicin HCl liposom
  • S-liposomální doxorubicin
  • Stealth liposomální doxorubicin
  • TLC D-99
  • Dox-SL
  • Lipozomální doxorubicin HCl
  • Lipozom doxorubicin hydrochlorid
  • Lipodox 50
  • Liposomální doxorubicin hydrochlorid
  • Pegylovaný liposomální doxorubicin
  • Doxorubicin lipozomální
Lék: Topotecan Hydrochloride

Given IV

Ostatní jména:
  • Hycamtin
  • Hycamptamin
  • SKF S-104864-A
  • Topotekan HCl
  • topotekan hydrochlorid (perorální)
  • Potactasol
  • Evotopin
  • Topotec
  • Nogitecan hydrochlorid
  • SKF S 104864 A
  • SKF S104864A
Postup: Computed Tomography with Contrast

Undergo CT with contrast

Ostatní jména:
  • Kontrastní počítačová tomografie
  • CT SKENOVÁNÍ S KONTRASTEM
  • CT skenování s kontrastem
  • CT s kontrastem
Experimentální: Arm II (durvalumab, cediranib maleate, olaparib)

Patients receive durvalumab IV over 60 minutes on day 1, cediranib maleate PO QD Monday through Friday, and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
Postup: Computed Tomography

Undergo CT

Ostatní jména:
  • ČT
  • KOČKA
  • CAT skenování
  • Počítačová axiální tomografie
  • Počítačová tomografie
  • CT vyšetření
  • tomografie
  • Počítačová axiální tomografie (postup)
  • Počítačová tomografie (CT).
  • Diagnostické skenování CAT
  • Typ služby diagnostického skenování CAT
Postup: Magnetic Resonance Imaging

Undergo MRI

Ostatní jména:
  • MRI
  • Magnetická rezonance
  • Skenování magnetickou rezonancí
  • Lékařské zobrazování, magnetická rezonance / nukleární magnetická rezonance
  • PAN
  • MR zobrazování
  • MRI skenování
  • NMR zobrazování
  • NMRI
  • Nukleární magnetická rezonance
  • Zobrazování magnetickou rezonancí (MRI)
  • sMRI
  • Magnetická rezonance (postup)
  • Strukturální MRI
Postup: Echocardiography Test

Undergo ECHO

Ostatní jména:
  • Echokardiografie
  • EC
Postup: Multigated Acquisition Scan

Undergo MUGA

Ostatní jména:
  • Skenování bazénu krve
  • Rovnovážná radionuklidová angiografie
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklidová ventrikulografie
  • RNVG
  • Skenování SYMA
  • Synchronizované multigated Acquisition Scanning
  • Skenování MUGA
  • Multi-Gated Acquisition Scan
  • Radionuklidový Ventrikulogram Scan
  • Gated Heart Pool Scan
  • Skenování RNV
Postup: Biospecimen Collection

Undergo collection of blood

Ostatní jména:
  • Sběr biologických vzorků
  • Odebrán biovzorek
  • Sbírka vzorků
Lék: Cediranib Maleate

Given PO

Ostatní jména:
  • AZD2171
  • AZD2171 maleát
  • Recentin
Lék: Olaparib

Given PO

Ostatní jména:
  • Lynparza
  • AZD 2281
  • AZD-2281
  • AZD2281
  • KU-0059436
  • Inhibitor PARP AZD2281
  • KU0059436
  • Olanib
  • Olaparix
  • KU 0059436
Postup: Computed Tomography with Contrast

Undergo CT with contrast

Ostatní jména:
  • Kontrastní počítačová tomografie
  • CT SKENOVÁNÍ S KONTRASTEM
  • CT skenování s kontrastem
  • CT s kontrastem
Biologický: Durvalumab

Given IV

Ostatní jména:
  • Imfinzi
  • Imunoglobulin G1, anti-(lidský protein B7-H1) (lidský monoklonální MEDI4736 těžký řetězec), disulfid s lidským monoklonálním MEDI4736 kappa-řetězcem, dimer
  • MEDI-4736
  • MEDI4736
  • MEDI 4736
Experimentální: Arm III (durvalumab, cediranib maleate)

Patients receive durvalumab IV over 60 minutes on day 1 and cediranib maleate PO QD Monday through Friday. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
Postup: Computed Tomography

Undergo CT

Ostatní jména:
  • ČT
  • KOČKA
  • CAT skenování
  • Počítačová axiální tomografie
  • Počítačová tomografie
  • CT vyšetření
  • tomografie
  • Počítačová axiální tomografie (postup)
  • Počítačová tomografie (CT).
  • Diagnostické skenování CAT
  • Typ služby diagnostického skenování CAT
Postup: Magnetic Resonance Imaging

Undergo MRI

Ostatní jména:
  • MRI
  • Magnetická rezonance
  • Skenování magnetickou rezonancí
  • Lékařské zobrazování, magnetická rezonance / nukleární magnetická rezonance
  • PAN
  • MR zobrazování
  • MRI skenování
  • NMR zobrazování
  • NMRI
  • Nukleární magnetická rezonance
  • Zobrazování magnetickou rezonancí (MRI)
  • sMRI
  • Magnetická rezonance (postup)
  • Strukturální MRI
Postup: Echocardiography Test

Undergo ECHO

Ostatní jména:
  • Echokardiografie
  • EC
Postup: Multigated Acquisition Scan

Undergo MUGA

Ostatní jména:
  • Skenování bazénu krve
  • Rovnovážná radionuklidová angiografie
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklidová ventrikulografie
  • RNVG
  • Skenování SYMA
  • Synchronizované multigated Acquisition Scanning
  • Skenování MUGA
  • Multi-Gated Acquisition Scan
  • Radionuklidový Ventrikulogram Scan
  • Gated Heart Pool Scan
  • Skenování RNV
Postup: Biospecimen Collection

Undergo collection of blood

Ostatní jména:
  • Sběr biologických vzorků
  • Odebrán biovzorek
  • Sbírka vzorků
Lék: Cediranib Maleate

Given PO

Ostatní jména:
  • AZD2171
  • AZD2171 maleát
  • Recentin
Postup: Computed Tomography with Contrast

Undergo CT with contrast

Ostatní jména:
  • Kontrastní počítačová tomografie
  • CT SKENOVÁNÍ S KONTRASTEM
  • CT skenování s kontrastem
  • CT s kontrastem
Biologický: Durvalumab

Given IV

Ostatní jména:
  • Imfinzi
  • Imunoglobulin G1, anti-(lidský protein B7-H1) (lidský monoklonální MEDI4736 těžký řetězec), disulfid s lidským monoklonálním MEDI4736 kappa-řetězcem, dimer
  • MEDI-4736
  • MEDI4736
  • MEDI 4736
Experimentální: Arm IV (cediranib maleate, olaparib)

Patients receive cediranib maleate PO QD on days 1-28 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
Postup: Computed Tomography

Undergo CT

Ostatní jména:
  • ČT
  • KOČKA
  • CAT skenování
  • Počítačová axiální tomografie
  • Počítačová tomografie
  • CT vyšetření
  • tomografie
  • Počítačová axiální tomografie (postup)
  • Počítačová tomografie (CT).
  • Diagnostické skenování CAT
  • Typ služby diagnostického skenování CAT
Postup: Magnetic Resonance Imaging

Undergo MRI

Ostatní jména:
  • MRI
  • Magnetická rezonance
  • Skenování magnetickou rezonancí
  • Lékařské zobrazování, magnetická rezonance / nukleární magnetická rezonance
  • PAN
  • MR zobrazování
  • MRI skenování
  • NMR zobrazování
  • NMRI
  • Nukleární magnetická rezonance
  • Zobrazování magnetickou rezonancí (MRI)
  • sMRI
  • Magnetická rezonance (postup)
  • Strukturální MRI
Postup: Echocardiography Test

Undergo ECHO

Ostatní jména:
  • Echokardiografie
  • EC
Postup: Biospecimen Collection

Undergo collection of blood

Ostatní jména:
  • Sběr biologických vzorků
  • Odebrán biovzorek
  • Sbírka vzorků
Lék: Cediranib Maleate

Given PO

Ostatní jména:
  • AZD2171
  • AZD2171 maleát
  • Recentin
Lék: Olaparib

Given PO

Ostatní jména:
  • Lynparza
  • AZD 2281
  • AZD-2281
  • AZD2281
  • KU-0059436
  • Inhibitor PARP AZD2281
  • KU0059436
  • Olanib
  • Olaparix
  • KU 0059436
Postup: Computed Tomography with Contrast

Undergo CT with contrast

Ostatní jména:
  • Kontrastní počítačová tomografie
  • CT SKENOVÁNÍ S KONTRASTEM
  • CT skenování s kontrastem
  • CT s kontrastem

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Progression Free Survival
Časové okno: From start of treatment to time of progression or death, whichever occurs first. Median follow-up time was 4.8 months (Inter-Quartile Range: 2.0-7.9 months).

The relationship of randomized treatment assignment to progression free survival. The RECIST 1.1 criteria are used for disease progression. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
From start of treatment to time of progression or death, whichever occurs first. Median follow-up time was 4.8 months (Inter-Quartile Range: 2.0-7.9 months).

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Objective Response Rate
Časové okno: From the start of the treatment until disease progression/recurrence, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.

Determination of response should take into consideration all target and non-target lesions. Here are the definitions of CR, PR, PD and SD: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters (i.e. the nadir) while on study. The CI is the Jeffreys interval.
From the start of the treatment until disease progression/recurrence, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
Duration of Response
Časové okno: Throughout study treatment, up to 10.6 months.

Tumor response was assessed using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1) criteria. Duration of response was defined as the time from the first documentation of objective tumor response (complete response (CR) or partial response (PR)) to the first documented progressive disease (PD), or to death due to any cause, whichever occurs first.

Per RECIST, Complete Response (CR) is defined as the disappearance of all target lesions; Partial Response (PR) is defined as an >=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Reporting the number of months from complete or partial response until disease progression, death or censoring, whichever occurs first. In the absence of disease progression or death, censoring time is based on date of last CT scan.
Throughout study treatment, up to 10.6 months.
Overall Survival
Časové okno: Time from study entry to date of death from any cause, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.

Overall survival will be presented by Kaplan Meier methods. Overall Survival (OS) is defined as the duration of time from study entry to date of death from any cause. A subject who has not died will be censored on the date that they were last known to be alive.
Time from study entry to date of death from any cause, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
Count of Participants With a Grade 3 (or Higher) Adverse Event
Časové okno: From the start of treatment until disease progression/recurrence or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.

The number of patients (in each reporting group) who experienced a grade 3 (or higher) adverse event
From the start of treatment until disease progression/recurrence or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

National Cancer Institute (NCI)

Spolupracovníci

NRG Oncology

Vyšetřovatelé

  • Vrchní vyšetřovatel: Jung-min Lee, NRG Oncology

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

10. června 2021

Primární dokončení (Aktuální)

26. ledna 2023

Dokončení studie (Odhadovaný)

25. června 2027

Termíny zápisu do studia

První předloženo

4. února 2021

První předloženo, které splnilo kritéria kontroly kvality

4. února 2021

První zveřejněno (Aktuální)

5. února 2021

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

22. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

21. října 2026

Naposledy ověřeno

1. července 2026

Více informací

Termíny související s touto studií

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • NCI-2021-00615
  • U10CA180868 (Grant/smlouva NIH USA)
  • NCI-2021-00615 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
  • NRG-GY023 (Jiný identifikátor: CTEP)
  • NRG-GY023 (Jiný identifikátor: NRG Oncology)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit